Manufacturer with High Purity and Stable Quality
Commercial Supply Sofosbuvir (CAS: 1190307-88-0) and Related Intermediates:
Sofosbuvir CAS: 1190307-88-0
N4-Benzoylcytosine CAS: 26661-13-2
triphenyl(1-[ethoxycarbonyl]ethylidene)phosphorane CAS: 21382-82-1
Pentafluorophenol CAS: 771-61-9
N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester CAS: 1334513-02-8
| Name | Sofosbuvir |
| CAS Number | 1190307-88-0 |
| CAT Number | RF-API06 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C22H29FN3O9P |
| Molecular Weight | 529.45 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Crystalline Powder |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Identification | HPLC RT |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.50% |
| Single Unknown Impurity | ≤0.50% |
| Total Impurities | ≤1.0% |
| Heavy Metals | ≤20ppm |
| Melting Point | 95.0~100.0℃ |
| Test Standard | Enterprise Standard |
| Usage | Sofosbuvir (CAS: 1190307-88-0) in the treatment of Hepatitis C Virus (HCV) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Manufacturer with High Purity and Stable Quality
Commercial Supply Sofosbuvir (CAS: 1190307-88-0) and Related Intermediates:
Sofosbuvir CAS: 1190307-88-0
N4-Benzoylcytosine CAS: 26661-13-2
triphenyl(1-[ethoxycarbonyl]ethylidene)phosphorane CAS: 21382-82-1
Pentafluorophenol CAS: 771-61-9
N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester CAS: 1334513-02-8
Sofosbuvir is a drug used for the treatment of hepatitis C. It is recommended to be used in combination with other drugs (such as velpatasvir) for the first-line treatment for HCV genotypes 1, 2, 3, 4, 5, and 6. It takes effect through acting as a nucleotide analog inhibitor, being capable of specially inhibiting the HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase. Oral sofosbuvir was generally well tolerated in patients with chronic hepatitis C. The most commonly reported adverse events and laboratory abnormalities in patients receiving sofosbuvir plus ribavirin with or without peginterferon-alpha were consistent with those expected in patients receiving treatment with ribavirin and peginterferon-alpha, and co-administering sofosbuvir did not appear to increase the frequency or severity of these adverse events or laboratory abnormalities.